FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1566978183> ?p ?o ?g. }

• W1566978183 endingPage "1566" @default.
• W1566978183 startingPage "1562" @default.
• W1566978183 abstract "Background Sorafenib is an oral small molecule inhibitor of multiple kinases controlling tumor growth and angiogenesis. The purpose of the phase 2 study was to determine the response rate of sorafenib and gain further information on the associated toxicities, pharmacokinetics, and pharmacodynamics of sorafenib in children and young adults with relapsed or refractory tumors including rhabdomyosarcoma, Wilms tumor, hepatocellular carcinoma (HCC), and papillary thyroid carcinoma (PTC). Procedure Sorafenib, 200 mg/m 2 /dose, was administered every 12 hr continuously for 28 day cycles using a two‐stage design in two primary strata (rhabdomyosarcoma and Wilms tumor) and two secondary strata (HCC and PTC). Correlative studies in consenting patients included determination of sorafenib steady state trough concentrations and assessments of VEGF and sVEGFR2. Results Twenty patients (median age of 11 years; range, 5–21) enrolled. No objective responses (RECIST) were observed in the 10 evaluable patients enrolled in each of the two primary disease strata of rhabdomyosarcoma and Wilms tumor. No patients with HCC or PTC were enrolled. Sorafenib was not associated with an excessive rate of dose‐limiting toxicity (DLT). The mean ± SD steady state concentration during cycle 1 day 15 was 6.5 ± 3.9 μg/ml (n = 10). Conclusions Sorafenib was well tolerated in children at 200 mg/m 2 /dose twice daily on a continuous regimen with toxicity profile and steady state drug concentrations similar to those previously reported. Single agent sorafenib was inactive in children with recurrent or refractory rhabdomyosarcoma or Wilms tumor. Pediatr Blood Cancer 2015;62:1562–1566. © 2015 Wiley Periodicals, Inc." @default.
• W1566978183 created "2016-06-24" @default.
• W1566978183 creator A5009042526 @default.
• W1566978183 creator A5027468886 @default.
• W1566978183 creator A5044409970 @default.
• W1566978183 creator A5050571054 @default.
• W1566978183 creator A5050738935 @default.
• W1566978183 creator A5071679104 @default.
• W1566978183 creator A5090325707 @default.
• W1566978183 date "2015-04-27" @default.
• W1566978183 modified "2023-10-06" @default.
• W1566978183 title "Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group" @default.
• W1566978183 cites W1971837077 @default.
• W1566978183 cites W1976382591 @default.
• W1566978183 cites W1983180167 @default.
• W1566978183 cites W1983602290 @default.
• W1566978183 cites W1985429138 @default.
• W1566978183 cites W1986512306 @default.
• W1566978183 cites W1999544371 @default.
• W1566978183 cites W1999966467 @default.
• W1566978183 cites W2022137597 @default.
• W1566978183 cites W2026340629 @default.
• W1566978183 cites W2037535290 @default.
• W1566978183 cites W2040894487 @default.
• W1566978183 cites W2048079618 @default.
• W1566978183 cites W2061345986 @default.
• W1566978183 cites W2061440729 @default.
• W1566978183 cites W2071628034 @default.
• W1566978183 cites W2093433762 @default.
• W1566978183 cites W2108300554 @default.
• W1566978183 cites W2111141701 @default.
• W1566978183 cites W2122724278 @default.
• W1566978183 cites W2123421036 @default.
• W1566978183 cites W2124462125 @default.
• W1566978183 cites W2130673296 @default.
• W1566978183 cites W2135400147 @default.
• W1566978183 cites W2135678285 @default.
• W1566978183 cites W2144530818 @default.
• W1566978183 cites W2151507583 @default.
• W1566978183 cites W2155008672 @default.
• W1566978183 cites W2158801409 @default.
• W1566978183 cites W2158927044 @default.
• W1566978183 cites W2165671989 @default.
• W1566978183 cites W2288605373 @default.
• W1566978183 cites W4237907217 @default.
• W1566978183 cites W4251458288 @default.
• W1566978183 doi "https://doi.org/10.1002/pbc.25548" @default.
• W1566978183 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4515771" @default.
• W1566978183 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26207356" @default.
• W1566978183 hasPublicationYear "2015" @default.
• W1566978183 type Work @default.
• W1566978183 sameAs 1566978183 @default.
• W1566978183 citedByCount "61" @default.
• W1566978183 countsByYear W15669781832016 @default.
• W1566978183 countsByYear W15669781832017 @default.
• W1566978183 countsByYear W15669781832018 @default.
• W1566978183 countsByYear W15669781832019 @default.
• W1566978183 countsByYear W15669781832020 @default.
• W1566978183 countsByYear W15669781832021 @default.
• W1566978183 countsByYear W15669781832022 @default.
• W1566978183 countsByYear W15669781832023 @default.
• W1566978183 crossrefType "journal-article" @default.
• W1566978183 hasAuthorship W1566978183A5009042526 @default.
• W1566978183 hasAuthorship W1566978183A5027468886 @default.
• W1566978183 hasAuthorship W1566978183A5044409970 @default.
• W1566978183 hasAuthorship W1566978183A5050571054 @default.
• W1566978183 hasAuthorship W1566978183A5050738935 @default.
• W1566978183 hasAuthorship W1566978183A5071679104 @default.
• W1566978183 hasAuthorship W1566978183A5090325707 @default.
• W1566978183 hasBestOaLocation W15669781832 @default.
• W1566978183 hasConcept C112705442 @default.
• W1566978183 hasConcept C121332964 @default.
• W1566978183 hasConcept C126322002 @default.
• W1566978183 hasConcept C142424586 @default.
• W1566978183 hasConcept C142724271 @default.
• W1566978183 hasConcept C143998085 @default.
• W1566978183 hasConcept C2775999222 @default.
• W1566978183 hasConcept C2776304256 @default.
• W1566978183 hasConcept C2778019345 @default.
• W1566978183 hasConcept C2778256501 @default.
• W1566978183 hasConcept C2778695046 @default.
• W1566978183 hasConcept C2779984678 @default.
• W1566978183 hasConcept C2780844630 @default.
• W1566978183 hasConcept C29730261 @default.
• W1566978183 hasConcept C31760486 @default.
• W1566978183 hasConcept C71924100 @default.
• W1566978183 hasConcept C87355193 @default.
• W1566978183 hasConceptScore W1566978183C112705442 @default.
• W1566978183 hasConceptScore W1566978183C121332964 @default.
• W1566978183 hasConceptScore W1566978183C126322002 @default.
• W1566978183 hasConceptScore W1566978183C142424586 @default.
• W1566978183 hasConceptScore W1566978183C142724271 @default.
• W1566978183 hasConceptScore W1566978183C143998085 @default.
• W1566978183 hasConceptScore W1566978183C2775999222 @default.
• W1566978183 hasConceptScore W1566978183C2776304256 @default.
• W1566978183 hasConceptScore W1566978183C2778019345 @default.
• W1566978183 hasConceptScore W1566978183C2778256501 @default.
• W1566978183 hasConceptScore W1566978183C2778695046 @default.

• next